Drug research

Darovasertib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as IDE 196; IDE196; LXS196

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954	IDEAYA Biosciences	Phase 2	Active not recruiting	2027-04-30Estimated
Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190	IDEAYA Biosciences	Phase 3	Recruiting	2030-10Estimated

IDEAYA BiosciencesActive not recruitingPrimary completion: 2027-04-30 · Estimated

Trial details

IDEAYA BiosciencesRecruitingPrimary completion: 2030-10 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.